Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

Macarena de la Fuente, MD, becomes the first Hispanic elected and will represent neurology on the multidisciplinary board.

Marijo Bilusic, MD, PhD, highlights key points presented at the meeting, including considerations with PARP inhibitor combinations for patients with mCRPC, how disease characteristics factor into treatment selection for patients with hormone-sensitive prostate cancer, and more.

Dolphins Challenge Cancer and AutoNation are teaming up to address the links between social, economic and environmental factors and breast cancer mortality.

State of the Science Summit - Lung Cancer: Chaired by Gilberto Lopes, MD

BioFlorida, a statewide association for Florida’s life sciences industry, has named Stephen D. Nimer, MD, director of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, “Researcher of the Year.”

Marijo Bilusic, MD, PhD, discusses updates seen in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Kaylie Cullison, an award-winning researcher, MD/PhD student and mentee to Dr. Eric Mellon, will present data on true progression and pseudoprogression with the use of the MRI-linac machine.

State of the Science Summit - Prostate/RCC: Chaired by Marijo Bilusic, MD, PhD

At the 17th Congress of the International Society of Behavioral Medicine, Dr. Penedo received the organization’s 2023 Distinguished Scientist Award.

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are part of an international team of scientists who identified mechanisms by which some multiple myelomas become resistant to initially effective T-cell therapies.

Sanoj Punnen, MD, the University of Miami Miller School of Medicine, is leading a $2.5 million, five-year National Cancer Institute grant to explore a new way to noninvasively detect prostate cancer.

Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.

Dr Trent discusses the need for improved awareness around mutation testing in GIST, the limitations of current clinical trial criteria, and the potential for ctDNA to become a longitudinal cancer monitoring tool, helping to prevent invasive means of measuring disease progression.

Jonathan C. Trent, MD, PhD, discusses data from 2 phase 2 trials of immunotherapy in soft tissue sarcoma, as well as their clinical significance.

Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.

One of the world’s foremost biochemists is joining Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, bringing decades of groundbreaking research in genetics, epigenetics and cellular processes.

Shria Kumar, MD, a colorectal cancer researcher with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has been awarded a Conquer Cancer Career Development Award from the American Society of Clinical Oncology.

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

The American Association for Cancer Research has selected Sylvester Comprehensive Cancer Center as one of the newest members of a worldwide consortium contributing genomic data to AACR’s Project GENIE.

Estelamari Rodriguez, MD, MPH, discusses the benefits of the TKIs afatinib and osimertinib in patients with lung cancer with uncommon EGFR mutations.

Justin W. Taylor, MD, discusses the evolution of frontline treatment options for patients with blastic plasmacytoid dendritic cell neoplasm, including the integration of tagraxofusp-erzs into the treatment armamentarium in this disease space.

Priyamvada Rai, PhD, is the new Tumor Biology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.

A large research project found that whole genome sequencing can provide much more information about classic Hodgkin lymphoma than exome sequencing, which reads only protein-coding genes.

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Jaime Merchán, MD, is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.

An international research group, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has developed a new machine learning algorithm that can combine large datasets from multiple sources to pinpoint kinases and potentially target them for treatment.

Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.

With three years to go, C. Ola Landgren, MD, PhD, is on track to establish a “top three” U.S. myeloma program within five years, with the announcement of the new, dedicated Myeloma Research Institute within Sylvester Comprehensive Cancer Center.